[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse UGP2

Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF01704 UTP--glucose-1-phosphate uridylyltransferase
Function

Plays a central role as a glucosyl donor in cellular metabolic pathways.

> Gene Ontology
 
Biological Process GO:0000271 polysaccharide biosynthetic process
GO:0005976 polysaccharide metabolic process
GO:0005977 glycogen metabolic process
GO:0005978 glycogen biosynthetic process
GO:0006011 UDP-glucose metabolic process
GO:0006065 UDP-glucuronate biosynthetic process
GO:0006073 cellular glucan metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006112 energy reserve metabolic process
GO:0009225 nucleotide-sugar metabolic process
GO:0009226 nucleotide-sugar biosynthetic process
GO:0009250 glucan biosynthetic process
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016051 carbohydrate biosynthetic process
GO:0019255 glucose 1-phosphate metabolic process
GO:0033692 cellular polysaccharide biosynthetic process
GO:0034637 cellular carbohydrate biosynthetic process
GO:0044042 glucan metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0046398 UDP-glucuronate metabolic process
Molecular Function GO:0003983 UTP:glucose-1-phosphate uridylyltransferase activity
GO:0005536 glucose binding
GO:0016779 nucleotidyltransferase activity
GO:0019103 pyrimidine nucleotide binding
GO:0030246 carbohydrate binding
GO:0032557 pyrimidine ribonucleotide binding
GO:0048029 monosaccharide binding
GO:0051748 UTP-monosaccharide-1-phosphate uridylyltransferase activity
GO:0070569 uridylyltransferase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00040 Pentose and glucuronate interconversions
hsa00052 Galactose metabolism
hsa00500 Starch and sucrose metabolism
hsa00520 Amino sugar and nucleotide sugar metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-211859: Biological oxidations
R-HSA-173599: Formation of the active cofactor, UDP-glucuronate
R-HSA-70326: Glucose metabolism
R-HSA-156588: Glucuronidation
R-HSA-3322077: Glycogen synthesis
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-156580: Phase II conjugation
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UGP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UGP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.45; FDR: 0.04150 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UGP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0030.993
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3090.906
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2220.907
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0770.828
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4060.846
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3430.9
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1670.737
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4430.823
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.210.927
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0020.999
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5710.854
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.030.603
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UGP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UGP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UGP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UGP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UGP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UGP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UGP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUGP2
NameUDP-glucose pyrophosphorylase 2
Aliases UGPP1; UGP1; UDP-glucose pyrophosphorylase 1; UDPG; UDPGP; UDPGP2; UGPP2; pHC379; UDP-glucose diphosphorylas ......
Chromosomal Location2p14-p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UGP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.